AstraZeneca ponders a China pharma spinoff to protect itself from geopolitical fallout — FT
As senior government officials in the US warily look to stabilize rocky relations with China, one global pharma giant has been considering a corporate restructuring that could help it sidestep the tense confrontation between the two countries that has developed in the last few years.
The Financial Times is reporting that AstraZeneca has been considering the pluses and minuses of spinning off its China assets into a separately listed company in either Hong Kong or Shanghai. Citing several bankers familiar with the deal, the FT highlights the preliminary nature of the conversations, noting that a host of multinationals with a stake in China have been doing exactly the same thing. (The FT owns a majority stake in Endpoints News, though the news organizations are independent.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.